Comparison of clinical characteristics between patients with NHL and patients with HD
| . | NHL . | HD . | . |
|---|---|---|---|
| No. of patients | 18 | 7 | |
| Age (y) | 65 | 55 | P = .04 |
| % male | 33 | 71 | P = .20 |
| Duration RA (y) | 17 | 15 | NS |
| Dose MTX (g) | 2.4 | 2.2 | NS |
| Duration MTX (mo) | 65 | 49 | NS |
| EBV | 3/18 | 5/7 | |
| Median overall survival (mo) | Not reached | 27 | NS |
| Remission after MTX WD alone | 3/5 | 0/3 | |
| Long-term remission after MTX WD alone | 1/5 | 0/3 |
| . | NHL . | HD . | . |
|---|---|---|---|
| No. of patients | 18 | 7 | |
| Age (y) | 65 | 55 | P = .04 |
| % male | 33 | 71 | P = .20 |
| Duration RA (y) | 17 | 15 | NS |
| Dose MTX (g) | 2.4 | 2.2 | NS |
| Duration MTX (mo) | 65 | 49 | NS |
| EBV | 3/18 | 5/7 | |
| Median overall survival (mo) | Not reached | 27 | NS |
| Remission after MTX WD alone | 3/5 | 0/3 | |
| Long-term remission after MTX WD alone | 1/5 | 0/3 |
NS indicates not significant; WD, withdrawal.